[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 17, 2013

Combination Therapy to Prevent Cardiovascular Disease: Slow Progress

Author Affiliations

Author Affiliations: UnitedHealth Chronic Disease Initiative, London, United Kingdom (Dr Smith); and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada (Drs McCready and Yusuf).

JAMA. 2013;309(15):1595-1596. doi:10.1001/jama.2013.3180

Cardiovascular disease is the major cause of mortality and morbidity globally and affects half of all individuals over their lifetimes.1 The burden of cardiovascular disease in developing countries is increasing substantially, and cardiovascular disease is becoming the leading cause of death.1 The concept of combining antihypertensive drugs, a statin, and aspirin into a single, fixed-dose, combination pill to prevent myocardial infarction and stroke is now a dozen years old, but still no such pill is licensed in most countries.